期刊
MABS
卷 1, 期 3, 页码 216-221出版社
LANDES BIOSCIENCE
DOI: 10.4161/mabs.1.3.8593
关键词
ustekinumab; CNTO-1275; Stelara; psoriasis; psoriatic arthritis; Crohn disease; multiple sclerosis
Ustekinumab is an anti-IL12/23 IgG1 kappa human monoclonal antibody currently undergoing US Food and Drug Administration review for use as a psoriasis treatment. The candidate has also been evaluated in Phase 2 studies as a treatment for psoriatic arthritis, Crohn disease and multiple sclerosis. In large clinical trials, ustekinumab has proven effective for treating moderate to severe plaque psoriasis. Although long-term follow-up studies are needed to address safety concerns, the hopes are high for psoriasis treatment. Ustekinumab has recently been approved for marketing in Canada and Europe.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据